AF-CX 921
AF-CX 921 is an orally active anticonvulsant agent. AF-CX 921 exhibits antiepileptic effects in ferrets, hippocampally kindled cats, and Mongolian gerbils. AF-CX 921 exhibits anticonvulsant activity in normal and microcephalic hippocampally kindled rats. AF-CX 921 can be used for the research of epileptic seizures and epilepsy.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 77946-49-7
- Formel: C15H11NOS
- Molecular Weight:253.32
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vivo
AF-CX 921 (100 mg/kg; p.o.; single dose) significantly reduces epileptic afterdischarge duration and convulsive seizure frequency, while increasing quiet states, in both normal and hippocampally kindled microcephalic adult rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Adult rats (microcephalic rats produced by maternal intraperitoneal injection of Methylazoxy-Methanol Acetate on gestation day 15; hippocampally kindled via daily electrical stimulation of ventral hippocampi)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced the duration of first afterdischarges (AD1) to 42.7 s in Part 1.
Reduced AD1 duration to 50.4 s in Part 2.
Reduced the frequency of focal hippocampal spiking (FS) to 17.5% in Part 1 and 23.0% in Part 2.
Reduced the frequency of second afterdischarges (AD2) to 25.0%.
Reduced total EEG epileptic activity (AD1 + FS + AD2) to 59.1 s in Part 1 and 63.6 s in Part 2.
Increased the frequency of quiet, non-responsive behavior (Q) to 64.2%.
Reduced the frequency of convulsive seizures (CS) to 21.1%.
Maintained significant suppression of CS for the full 5-hour testing period, unlike carbamazepine which lost most effect after 4-5 hours.
-
Animal Model:Adult rats (hippocampally kindled; microcephaly induced by maternal i.p. injection of 30 mg/kg MethylazoxymethAnol Acetate on gestation day 15)[2]
-
Dosage:100 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced mean early afterdischarge (AD1) duration in normal rats.
Increased quiet state (Q) occurrence in normal rats.
Reduced convulsive seizure (CS) occurrence in normal rats.
Reduced mean AD1 duration in microcephalic rats.
Increased Q occurrence in microcephalic rats.
Reduced CS occurrence in microcephalic rats.
Chemical Information
-
CAS. Nr. 77946-49-7
-
Molecular Weight 253.32
-
Formel C15H11NOS
-
SMILES
O=C1C2=CC=CC=C2S/C1=C(N)\C3=CC=CC=C3
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Majkowski J, et al. Effects of carbamazepine, AF-CX 921, and AF-CX 1325 on epileptic discharges and seizures in hippocampally kindled rats. Epilepsia. 1986 Jul-Aug;27(4):391-8. [Content Brief]
[2]. Majkowski J, et al. Differences in antiepileptic drug efficacy in hippocampally kindled normal and microcephalic rats. Brain Res. 1986 Oct 29;386(1-2):325-31. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
AF-CX 921 Related Classifications
HY-138058 Related Classifications
Powered by Bioz